CHP Fund Veda Global Letters About Contact
About

Building lasting wealth through concentrated, high-conviction investing in US equities and India’s highest-quality businesses.

Columbia Heights manages two specialized long-only equity funds focused on quality growth businesses with sustainable competitive advantages — companies demonstrating strong growth trajectories, robust cash generation, exceptional return on equity, and genuine pricing power.


+228%
CHP cumulative net return
since 2019 inception
18%
CHP net IRR vs. 15% S&P 500
over same period
+116%
Veda Global cumulative return
since 2021 inception
26%
Veda Global net IRR
+69% in 2024

Our Funds

Inquire →
US Equity · Inception 2019
Columbia Heights Partners, LP
A concentrated long-only US equity fund. CHP has compounded at 18% annually since 2019 inception — $328 today on every $100 invested, versus $273 in the S&P 500. All returns net of fees. We seek monopoly-like businesses with high ROE, strong margins, and sustainable long-term growth.
+228%
Since Inception
18%
Net IRR
3.3×
vs. 2.7× S&P 500

Learn More →

The 50/50/50 Framework

We invest only in businesses with ROE above 50%, operating margins above 50%, and long growth runways.

  • FICO — dominant credit scoring monopoly; re-entered at $1,300; projecting $40 EPS in 2026
  • EchoStar — spectrum sale to SpaceX; purchased at $70, NAV $260–$300
  • Tesla — long-term energy and autonomy optionality
  • Monopoly Watch List — ASML, TSM, MA, V, SPGI, MCO, MSCI
India Equity · Inception 2021
Veda Global, LP
A concentrated long-only India equity fund capturing the structural multi-decade growth story through India’s highest-quality financial services businesses. Veda returned +69% in 2024 alone. India’s economy — currently $5 trillion — is projected to become a top-3 global GDP.
+116%
Since Inception
26%
Net IRR
+69%
2024 Return

Learn More →

India’s Natural Monopolies

Every Veda holding falls in Buffett’s “Great” category — businesses earning high returns that rise as the years pass.

  • NSE — National Stock Exchange; dominant market infrastructure monopoly; purchased at 660 INR (12× PE), now 2000 INR
  • CRISIL Ratings — S&P Global subsidiary; pricing power + structural growth
  • CARE Ratings — oligopoly; per-capita credit at $0.02–$0.04 vs. $12–$18 in US
  • ICRA Ratings — Moody’s subsidiary; exceptional ROE and capital efficiency

Latest Letters

All Letters →

Sign up for our latest letters and fund updates.

Quarterly and annual letters via Substack. LP inquiries to gk@columbiaheights.co.

Or subscribe at gorav.substack.com